Increased expression of sialyl Lewis(x) antigen as a prognostic factor in patients with stage 0, I, and II gastric cancer.
Immunohistochemically detected expression of sialyl Lewis(x) (Le(x)) antigen was analyzed in 101 stage 0-II gastric cancers to clarify its prognostic value after curative gastrectomy. Patients with a high-expression of sialyl Le(x) antigen within their tumors had shorter disease-specific intervals than those with negative- or low-expressing tumors (P<0.0001). This difference was noted particularly in stage I-B or II disease. Multivariate Cox's regression analysis revealed sialyl Le(x) antigen expression to be an independent predictor of disease-specific survival (Hazard ratio=9.10). In conclusion, the increased expression of sialyl Le(x) antigen may serve as a prognostic factor after curative surgery for stages 0-II gastric cancer.
Nakagoe
Tohru
T
First Department of Surgery, Nagasaki University School of Medicine, 1-7-1 Sakamoto, 852-8501, Nagasaki, Japan. nakagoe@net.nagasaki-u.ac.jp
Fukushima
Kiyoyasu
K
Sawai
Terumitsu
T
Tsuji
Takashi
T
Jibiki
Masa aki
Ma
Nanashima
Atsushi
A
Tanaka
Kenji
K
Yamaguchi
Hiroyuki
H
Yasutake
Toru
T
Ayabe
Hiroyoshi
H
Arisawa
Kokichi
K
Ishikawa
Hiroshi
H
D006801:Humans; D007983:Lewis Blood Group Antigens / Q000235:genetics*; D009367:Neoplasm Staging; D009844:Oligosaccharides / Q000096:biosynthesis*; D011379:Prognosis; D000080506:Sialyl Lewis X Antigen; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology*; D015996:Survival Rate; D013997:Time Factors
D007983:Lewis Blood Group Antigens; D009844:Oligosaccharides; D000080506:Sialyl Lewis X Antigen